Home > Cluster Organisations > Biocat (Bioregion of Catalonia)

Biocat (Bioregion of Catalonia)

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
Year Established: 
Tuesday, 14 February, 2006
Number of employees in the cluster organisation : 
11-20
Regions: 
Cataluña
Cluster Excellence Label: 
Other
Membership to European Strategic Cluster Partnerships (ESCP-4i): 
Membership to other networks/partnerships: 
Cluster Management Team: 
NameSurnamePositionTelephoneEmail
Jordi
Fàbrega
Internationalisation Responsible
0034933103330
jfabrega@biocat.cat
Languages spoken: 
English
Spanish
Sectoral and Industrial Focus
Sectoral Industries: 
Biopharmaceuticals
Education and Knowledge Creation
S3 EU priority areas: 
e-Health (e.g. healthy ageing)
Human health activities (medical services)
Public health and well-being
Emerging industries: 
Bio-pharmaceuticals
Medical Devices
Composition of the cluster
Total number of members: 
734
Number of SME members: 
500
Number of larger company members: 
70
Number of research organisations/universities/technology centres: 
92
Name and link of major players: 
Website
Cluster Strategy
Mission/Objectives: 

Biocat is the organization that coordinates and promotes the life sciences and healthcare sector in Catalonia, the most dynamic bioregion in Spain. Its mission is to dynamize and support the public and private stakeholders that make up the BioRegion, the biosciences cluster in Catalonia, including companies, research groups and bodies, hospitals, universities, administrations and knowledge- and innovation-transfer support structures. In order to carry out this mission, Biocat promotes initiatives to encourage research, innovation and business growth, with the aim of making this sector a driving force for the Catalan economy and boosting its global recognition.

Set up as a public/private foundation, the Biocat governing bodies include representatives from all levels of the BioRegion of Catalonia: companies (biotechnology, pharmaceutical, medical technology and sector services), government, universities, hospitals, research centers and institutes, science parks and sector support bodies. 

Do you have a formalised strategy?: 
Yes
Do you have a specific strategy focus that addresses internationalisation ?: 
Yes
Services
Support services provided: 
Internationalisation support (= Access to third countries markets)
Access to public support (regional/national programmes, innovation vouchers, etc.)
Facilitation of collaboration between members
Trend-scouting (Ideas for innovative projects)
Promotion of activities (marketing/ visibility)
Cooperation Activities
International Cooperation
The main countries addressed by the cluster organisation through international activities: 
Brazil
Canada
China
Japan
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries addressed by the cluster organisation through trans-national activities: 
France
Germany
Italy
Portugal
United Kingdom
Our cluster organisation undertook the following trans-national activities to support our members: 
Participation at missions/events/study visits/fairs
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject NameLinkName & Description (Regional/National)Link (Regional/National)
H2020
CIP/COSME
INTERREG
EIT KICs

bioXclusters+ 2016-2018

bioXclusters+  is a continuation of bioXclusters, first initiative funded by the EC from 2012 to 2014. The initiative gathers4 cluster partners: Biocat (Catalonia), BioM (Bavaria), bioPmed/Bioindustry Park Silvano Fumero (Piemonte) and Lyonbiopole (Rhône-Alpes, project leader), aiming to reinforce and promote international competitiveness of their SMEs on strategic global markets.

EIT Health 2015-2020

The European EIT Health project is a consortium with nodes in Barcelona, Paris (France), London (United Kingdom), Rotterdam (Benelux), Stockholm (Sweden/Denmark) and Heidelberg (Germany). It is comprised of more than 50 core partners and 90 associated partners from 14 countries in the European Union, all of which are committed to innovation in health and its impact on improving quality of life. Biocat, which has been working to promote this initiative since 2009, is an associate member of EIT Health and has participated actively in drafting and coordinating the proposal for the Spanish node.

BILAT USA 2.0 2012-2015

Bilat USA 2.0 is a project under the European Commission’s 7th Framework Program (7FP) that promotes cooperation in science, technology and innovation between Europe and the United States. In addition to Catalonia, eight other European countries and four prestigious American bodies are participating. 

Transbio SUDOE 2013-2015

Transbio SUDOE is the continuation of the Interbio project, aimed at uniting research centers, technology platforms, universities and companies in eight regions in Spain, France and Portugal in a multidisciplinary network to more effectively transform the results of biotechnology research into economic results. 

bioXclusters 2012-2013

bioXclusters was a project carried out with support from the European Union that aimed to boost and promote the international competitiveness of biotechnology SMEs in three strategic markets: the United States, China and Brazil. 

ETTBio 2012-2014

ETTBio was an Interreg IVC international cooperation program geared towards identifying, exchanging and sharing best practices for technology transfer in biotechnology with the final goal of improving regional policies in this area. It has ten partners from seven European regions. 

HealthTIES 2010-2013

HealthTIES was a consortium made up of four European regions that aimed to promote innovation in medical technology and bridge the gap between research in this area and patient needs. 

Interbio 2009-2012

Interbio was an interregional cooperation program that aimed to foster transnational cooperation, technology transfer and innovation in the fields of biotechnology and the life sciences in southwestern Europe. 

Bio-CT 2009-2011

Bio-CT aimed to valorize projects and create biotechnology companies. Participants included bodies from Germany, France, Hungary, Italy, the United Kingdom and Catalonia.

RIS3CAT communities bid

The Government of Catalonia is launching the RIS3CAT Communities, a pioneering strategy in Europe that aims to transform the business fabric in Catalonia through 2020. The initiative is the practical application of the RIS3CAT Smart Specialization Strategy, passed by the Catalan government last year in response to the directives established by the European Union in the Europe 2020 Strategy.

In this context, Biocat is coordinating and dynamizing the creation of a future RIS3CAT community in Innovation and Health, to address the main health-related challenges today. 

Relevant Project References: 
EIT Health, bioXclusters, Transbio SUDOE, d·Health Barcelona, ETTBio, Bilat USA 2.0,
Promotion
Success Story / Achievements: 

One of Biocat’s main goals is to strengthen the BioRegion of Catalonia, to help the biocluster take a qualitative leap forward both nationally and internationally. This is why Biocat is working on a series of strategic projects on different levels. 

EIT Health, Biocat’s commitment to Europe, is a program devoted to innovation in health and its impact on improving quality of life. The Barcelona Clinical Trials Platform (BCTP) aims to position Catalonia among the top 5 areas in Spain for conducting clinical trials, bringing coordination, integration, quality and speed to clinical trials carried out here. 

Moreover, Biocat is also dynamizing and coordinating the creation of a future RIS3CAT community to address Catalonia’s main health-related challenges, from knowledge to market access. 

Why partners should choose you for cooperation?: 

From basic research to manufacturing and marketing new drugs or innovative medical devices, the whole biosciences sector is global, and the ability of Catalan companies to act and compete in this environment is key to their development and viability in the future.